Vanguard Capital Management
DMAC icon

Vanguard Capital Management’s DiaMedica Therapeutics DMAC Stock Holding History

Vanguard Capital Management’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.98M Buy
360,556
+5,033
+1% +$35.2K ﹤0.01% 3235
2026
Q2 		$2.5M Buy
355,523
+22,067
+7% +$136K ﹤0.01% 3340
2026
Q1 		$2.26M Buy
+333,456
New +$2.64M ﹤0.01% 3321

Other funds holding DMAC

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Bleichroeder LP
Bleichroeder LP New York $1.02B AUM 33% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Cobalt Capital Management
Cobalt Capital Management Short Hills, New Jersey $174M AUM 39.41% 1-Year Est. Return

Vanguard Capital Management's DMAC Position: Q3 2026 in Review

Vanguard Capital Management increased its DiaMedica Therapeutics (DMAC) stake by 1.4% in Q3 2026, buying an estimated $35.2K and bringing the position to 360,556 shares worth $2.98M. The position accounts for ﹤0.01% of the portfolio, ranked #3235.

Vanguard Capital Management first reported a position in DMAC in Q1 2026 and has held it in 3 quarters since. 67 funds tracked by Wall St. Rank hold DMAC as of Q3 2026.

  • Vanguard Capital Management held 360,556 shares of DiaMedica Therapeutics worth $2.98M as of Q3 2026.
  • Vanguard Capital Management bought 5,033 DiaMedica Therapeutics shares in Q3 2026, an estimated $35.2K.
  • DiaMedica Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3235 holding.
  • Vanguard Capital Management first reported a position in DiaMedica Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 67 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.